Evaluation of Linezolid and Vancomycin in the treatment of Methicillin-Resistant Staphylococcus aureus(MRSA) in Cystic Fibrosis Patients
Abstract
Background: Cystic fibrosis (CF) patients often have pulmonary colonization with multiple organisms, including MRSA, resulting in frequent hospitalizations and decreased quality of life. The pupose of this study was to evaluate the clinical efficacy of linezolid (LZD) and vancomycin (VAN) in the treatment of MRSA in the CF population.
Methods: A case series study was conducted with CF patients with pulmonary exacerbation and sputum culture positive for MRSA. Patients were received intravenous LZD or VAN. The primary endpoint was microbiological eradication of MRSA and secondary endpoints included Kanga Clinical Score (KS) and change in quality of life questionaire (CF QOL) score. Patients were followed for 6 months post treatment.
Results: Eight subjects were randomized to receive LZD (n=5) or VAN (n=3), with average duration of therapy of 19.8 and 21 days, respectively. The primary endpoint of microbiological eradication at end of treatment (EOT) was achieved in 3 patients treated with LZD and 2 with VAN. KS calculated at baseline and EOT showed a significant decrease in all subjects from a median of 26/50 to 16/50. Six patients or caregivers completed the CF QOL questionnaire. Five patients (2 treated with LZD, 3 with VAN) had improvements in CFQOL scores at EOT. No clinically significant adverse events were noted during the study.
Conclusions: No difference was noted between VAN and LZD in eradication of MRSA in CF patients with pulmonary exacerbation, nor in improvement in KS or CF QOL. Eradication of MRSA was less likely in patients with long-standing infection.
About this article
References
Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med. 2003;2(4):321-332.
Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr Pulmonol. 2002;33:221-223.
Thomas SR, Gyi KM, Gaya H et al. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect. 1998;40:203-209.
Boxerbaum B, Jacobs MR, Chechner RL. Prevalence and significance of methicillin-resistant Staphyloccus aureus in patients with cystic fibrosis. Pediatr Pulmonol. 1988;4:159-163.
Givney R, Vcikery A, Holliday A, et al. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J Hosp Infect. 1977;35:27-36.
View more references (20)
Miall LS, McGinley NT, Brownlee KG, et al. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child. 2001;84:160-162.
Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999;340:493-501.
Drew R. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacother. 2007;27:227-249.
Garske L, Kidd R, Gan R, et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect. 2004;56:208-214.
Serisier DJ, Jones G, Carroll M. Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid (correspondence). J Cystic Fibrosis. 2004;3:61.
Solis A, Brown D, Hughes J, et al. Methicillin-Resistant Staphylococcus aureus in Children with Cystic Fibrosis: An Eradication Protocol. Pediatr Pulmonol. 2003;36:189-195.
Ren C, Morgan W, Konstan M et al. Presence of Methicillin Resistant Staphylococcus aureus in Respiratory Cultures from Cystic Fibrosis Patients is Associated with Lower Lung Function. Pediatr Pulmonol. 2007;42:513-518.
Beydon N, Davis SD, Lombardi E, et al. An Official American Thoracic/European Respiratory Society Statement: Pulmonary Function Testing in Preschool Children. Am J Respir Crit Care Med. 2007;175:1304-1345.
Quittner AL, Buu A, Messer MA, et al. Development and Validation of the Cystic Fibrosis Questionnaire in the United States. Chest. 2005;128:2347-2354.
Matouk E, Ghezzo RH, Gruber J, et al. Internal consistency reliability and predictive validity of a modified N. Huang clinical scoring system in adult cystic fibrosis patients. Eur Respir J. 1997;10:2004-2013.
Miller MR, Crapo R, Hankinson J, et al. General Considerations for lung function testing. “ATS/ERS Task Force: Standardization of Lung function Testing.” Eur Respir J. 2005;26:153-161.
Quittner AL, Buu A, Messer MA, et al. Development and Validation of the Cystic Fibrosis Questionnaire in the United States. Chest. 2005;128:2347-2354.
Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J. 2009;33:305-11.
Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into lung tissue. J Antimicrob Chemother. 1996;38:865-69.
Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of linezolid to healthy human subjects. Drug Metab Dispos. 2001;29:1136-45.
Ager S, Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist. 2012;5:87-102.
Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator associated pneumonia. Crit. Care Med. 2005;33:1529-33.
Falagas M and Vardaka K. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Saf. 2008;31:753-68.
Bergeron L, Boule M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother. 2005;39:956-61.
Cystic Fibrosis Foundation Patient Registry, 2011 Annual Data Report to the Center Directors. Bethesda, Maryland: Cystic Fibrosis Foundation, 2012.